CTOs on the Move

Aditx Therapeutics

www.aditxt.com

 
Prolonging Life and Enhancing its Quality Technology to improve the health of your immune system Learn more about our technology AditxtScore™ AditxtReprogramming™ AditxtScore™
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aditxt.com
  • 2569, Wyandotte Street
    Mountain View, CA USA 94043
  • Phone: 951.316.9002

Executives

Name Title Contact Details

Similar Companies

Fore Biotherapeutics

As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.

Resilience Technology Corporation

Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

GVB Biopharma

GVB Biopharma operates two state-of-the-art hemp extraction and white labeling facilities in Central Oregon and Las Vegas, Nevada.

Osel Inc

Osel Inc is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.